Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026Indian Journal of Pharmacology

Systemic pathways linking subcutaneous therapies to gastrointestinal adverse effects: A Narrative review of mechanisms and mitigation strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

ASArun Kumar SinghDYDinesh YadavMSMadhusudan Prasad Singh

Discussion

Loading...

Member takes

Overview

Narrative review evaluates mechanisms and prevention strategies for gastrointestinal issues from subcutaneous therapies, indicating significant implications for clinical practice.

Key Points

  • This review aims to evaluate the mechanisms and prevention strategies for gastrointestinal adverse effects related to subcutaneous drug therapies.
  • Conducted a comprehensive literature search in PubMed, EMBASE, and Cochrane Library from January 2000 to June 2025.
  • Included randomized trials, observational studies, systematic reviews, and meta-analyses reporting on GI adverse effects.
  • Analyzed drug classes such as metabolic agents, cytokine modulators, and biologic therapies.
  • Subcutaneous therapies showed a wide range of GI adverse effects, including nausea, vomiting, and diarrhea.
  • Mechanistic pathways included delayed gastric emptying and immune activation, impacting treatment adherence.
  • Mitigation strategies involve dose titration and dietary modifications to enhance tolerability.

Cite This Study

Singh et al. (2026) studied this question.

synapsesocial.com/papers/6a3f6843aea7db3c1953f59dhttps://doi.org/10.4103/ijp.ijp_1343_25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gastrointestinal Toxicities of Targeted Cancer Therapies: A Narrative Review2026
  2. 2Challenging the myths of subcutaneous delivery: An industry expert perspective2026
  3. 3Comparable immunogenicity of new modality biotherapeutics delivered subcutaneously or intravenously in non-human primates2025
  4. 4Iatrogenic effect of immune checkpoint inhibitors and targeted therapies on the lower gastrointestinal tract2025
  5. 5Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system2024 · 9 citations